The downregulation of Mcl-1 via USP9X inhibition sensitizes solid tumors to Bcl-xl inhibition

Chander Peddaboina, Daniel Jupiter, Steven Fletcher, Jeremy L. Yap, Arun Rai, Richard P. Tobin, Weihua Jiang, Philip Rascoe, M. Karen N. Rogers, W. R. Smythe, Xiaobo Cao

Research output: Contribution to journalArticle

60 Scopus citations

Abstract

Background: It has been shown in many solid tumors that the overexpression of the pro-survival Bcl-2 family members Bcl-xL and Mcl-1 confers resistance to a variety of chemotherapeutic agents. Mcl-1 is a critical survival protein in a variety of cell lineages and is critically regulated via ubiquitination.Methods: The Mcl-1, Bcl-xL and USP9X expression patterns in human lung and colon adenocarcinomas were evaluated via immunohistochemistry. Interaction between USP9X and Mcl-1 was demonstrated by immunoprecipitation-western blotting. The protein expression profiles of Mcl-1, Bcl-xL and USP9X in multiple cancer cell lines were determined by western blotting. Annexin-V staining and cleaved PARP western blotting were used to assay for apoptosis. The cellular toxicities after various treatments were measured via the XTT assay.Results: In our current analysis of colon and lung cancer samples, we demonstrate that Mcl-1 and Bcl-xL are overexpressed and also co-exist in many tumors and that the expression levels of both genes correlate with the clinical staging. The downregulation of Mcl-1 or Bcl-xL via RNAi was found to increase the sensitivity of the tumor cells to chemotherapy. Furthermore, our analyses revealed that USP9X expression correlates with that of Mcl-1 in human cancer tissue samples. We additionally found that the USP9X inhibitor WP1130 promotes Mcl-1 degradation and increases tumor cell sensitivity to chemotherapies. Moreover, the combination of WP1130 and ABT-737, a well-documented Bcl-xL inhibitor, demonstrated a chemotherapeutic synergy and promoted apoptosis in different tumor cells.Conclusion: Mcl-1, Bcl-xL and USP9X overexpression are tumor survival mechanisms protective against chemotherapy. USP9X inhibition increases tumor cell sensitivity to various chemotherapeutic agents including Bcl-2/Bcl-xL inhibitors.

Original languageEnglish (US)
Article number541
JournalBMC Cancer
Volume12
DOIs
StatePublished - Nov 21 2012

Keywords

  • Bcl-xL
  • Cancer
  • Mcl-1
  • USP9X
  • Ubiquitination

ASJC Scopus subject areas

  • Genetics
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'The downregulation of Mcl-1 via USP9X inhibition sensitizes solid tumors to Bcl-xl inhibition'. Together they form a unique fingerprint.

  • Cite this

    Peddaboina, C., Jupiter, D., Fletcher, S., Yap, J. L., Rai, A., Tobin, R. P., Jiang, W., Rascoe, P., Rogers, M. K. N., Smythe, W. R., & Cao, X. (2012). The downregulation of Mcl-1 via USP9X inhibition sensitizes solid tumors to Bcl-xl inhibition. BMC Cancer, 12, [541]. https://doi.org/10.1186/1471-2407-12-541